Skip to main content
impaact logo Return to homepage
  • Contact
    • Directory
  • About
    • Mission
    • Network Structure
      • Leadership
    • Areas of Research
      • HIV Complications and Co-Morbidities
      • HIV Cure
      • HIV Treatment
      • Tuberculosis
    • Funding Acknowledgements
    • Network Sites
    • Staff Spotlight
  • Studies
    • Research and Study Opportunities
    • Submit a Research Proposal
    • IMPAACT Study Snapshots
  • Community Engagement
    • ICAB Leadership Group
    • IMPAACT Community Advisory Board (ICAB)
    • Operations Center Staff
    • Resources
      • Acronyms
    • Site Community Advisory Boards
  • News & Events
    • Conferences & Other Meetings
    • IMPAACT Annual Meeting
    • Newsletters
    • Past Conference Presentations
  • Resources
    • COVID-19 Resources
    • HIV/AIDS Network Coordination (HANC)
    • Lab Center
      • Laboratory Committees
      • Laboratory Guidance Documents
      • Laboratory Resources for Quality Management
      • Specimen Repository
    • Manual of Procedures
    • Network Logos & Templates
    • Regulatory Resources
    • Training Opportunities
  • Publications
    • Abstracts
    • Manuscripts
  • Enter a search term.
Back to Directory

Katie S. McCarthy

Email

Phone

Institution

FHI 360

Role

Clinical Research Associate

Address

FHI 360
359 Blackwell St.
Suite 200
Durham, NC 27701
United States of America
Request an Update

Affiliated Studies

1077BF: PROMISE 1077BF

DAIDS Number

10777

Research Area

Prevention

Study Status

Participants Off Study and Primary Analysis Completed

Locality

Non-US

P1060: NNRTI-Based vs. PI-Based ART in Infants Exposed/Not Exposed to NVP for PMTCT

DAIDS Number

10166

Research Area

Treatment

Study Status

Concluded

Locality

Non-US

1077FF: PROMISE 1077FF

DAIDS Number

10778

Research Area

Prevention

Study Status

Participants Off Study and Primary Analysis Completed

Locality

Non-US

IMPAACT 2014: Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-infected Children and Adolescents

DAIDS Number

34150

Research Area

Treatment

Study Status

Closed to Accrual

Locality

US & Non-US

P1084s: Maternal Infant TDF Toxicity Safety

DAIDS Number

10790

Research Area

Complications & Comorbidities

Study Status

Closed to Follow Up

Locality

Non-US
Show All
IMPAACT logo Return to homepage

Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.

Stay connected with the IMPAACT Network

Follow IMPAACT

Sign up for our newsletter

Sitemap

© 2020 IMPAACT Network